PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE erwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/625,073-Conf. #9446	
INF	ORMATI	ON DISC	CLOSURE	Filing Date	July 22, 2003	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Mark I. Greene	
				Art Unit	1617	
	(Use as man	y sheets as ne	cessary)	Examiner Name	L. M. Williams	
Sheet	1	of	1	Attorney Docket Number	20273/100K201-US2	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	76		
	BA	WO-01/08699-A1	02-08-2001	THE TRUSTEES OF THE		Г		
/LW	4	1		UNIVERSITY OF		ł		
				PENNSYLVANIA, et al.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	// conord \Alilliama/ (00/20/2007)	Date
	Leonard Williams/ (08/28/2007)	12
Signature		Considered

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/S8/08a/b (08-03)
Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requir

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

			f
Sheet	1	of	1

•	* Complete if Known				
Application Number	10/625,073				
Filing Date	July 22, 2003				
First Named Inventor	Mark I. Greene				
Art Unit	1653				
Examiner Name	A. A. Mohamed				
Attorney Docket Number	04040/100K201-US2				

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.'	Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear		
	ВА	WO-00/15807-A1	03-23-2000	Halkier et al.			
/LW/	BB	WO-00/01349-A2	01-13-2000	Murali et al.			

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Leonard Williams/ (08/28/2007)	Date Considered

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

PTC/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a coffection of information unless it displays a valid OMB control number.

Sub	estitute for form 1449/PTO			Complete If Known		
				Application Number	Not Yet Assigned	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Mark I. Greene	
				Art Unit	1653	
	(use as many sheets as necessary)			Examiner Name	A. Mohamed	
Sheet	1	of	3	Attorney Docket Number	4040/1K201US2	

	U.S. PATENT DOCUMENTS						
Examiner		Cita	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials		Cite No.1	Number-Kind Code ² (#known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
7L\	M/	AA.	4,215,051	7/29/80	Schroeder et al.		
		AB.	4,946,778	8/7/90	Ladner et al.		
		AC.	5,470,952	11/28/95	Stahl et al.		
		AD.	5,849,865	12/15/98	Cheng et al.		
	1	AE.	5,955,425		Morley et al.		
_/	7	AF.	5,985,832	11/16/99	Roodman et al.		
71	W/	AG.	5,869,452		Ng et al.		

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)	MW-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
TLW/		EP 0 045 665	5/8/81				
7LW/	ΑI	WO 98/53842	12/3/1998				
/I.W/	AJ	WO 99/58674	11/18/99				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the application number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
	No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
/LW/	AK	Ahmed et al., The Journal of Biological Chemistry, 250(21):8477-8482, November 1975			
	AL	Albericio et al., Int. J. Peptide Protein Res. 26:92-97, 1985			
	AM	Anderson et al. Nature, Vol. 390, pp. 175-179, November 13, 1997			
	AN Banner et al., Cell, 73:431-445, May 1993				
	AO	Beutler et al., Science, 264:667-668, April 1994			
	AP	Beutler et al., Annals of The New York Academy of Sciences, 730:118-133, 1994			
	AQ	Bowie et al. Science, Vol. 247, pp. 1306-1310, 1990			
	AR	Brisson et al., Nature, 310:511-514, August 1984			
	AS	Broglie et al., Science 224:838-843, May 1984			
	AT	Bucay et al., Genes Dev., 12(9):1260-1268, 1998	1		
	AU	Cole et al., Monoclonal Antibodies and Cancer Therapy, 77-96, January-February 1985			
	AV	Coruzzi et al., The EMBO Journal 3(8):1671-1679	l		
	AW	Cote et al., Proc. Natl. Acad. Sci. USA, 80:2026-2030, 1983			
7/	AX	Döring et al., Molecular Immunology, 31(14):1059-1067, 1994			
V	AY	Filvaroff, Current Biology, 8:R679-682, 1998			
/LW/	AZ	Fox et al. Biochem. Biphys. Res. Comm., Vol. 276, pp. 868-872, 2000			

Examiner	/Leonard Williams/ (08/28/2007)	Date
	Leonard Williams/ (08/28/2007)	150.0
Signature	7200/fara 77/mai/16/ (00/20/2007)	Considered
313.13.0		Considered

PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substi	tute for form 1449/P	то		Complete if Known	
				Application Number	Not Yet Assigned
INF	ORMATI	ON DISC	LOSURE	Filing Date	Concurrently Herewith
ST	ATEMEN	T BY AP	PLICANT	First Named Inventor	Mark I. Greene
				Art Unit	1653
	(use as many sheets as necessary)			Examiner Name	A. Mohamed
Sheet	2	of	3	Attorney Docket Number	4040/1K201US2

/LW/	ВА	Fingl et al., "General Principles," In: The Pharmacological Basis of Therapeutics, Chapter 1, 1-46, 1975	
	ВВ	Fuller, K., et al., "TRANCE is necessary and sufficient for osteoblastmediated activation of	
1	1	bone resorption in osteoclasts," Database Chemical Abstracts on STN, No. 129:314804,	İ
├─┼	DC -	Abstract, J. Exp. Med., 1998, 188(5), 997-1001	
} —-	BC	Gruss et al., Cytokines and Molecular Therapy 1:75-105, May 1995	
	BD	Gurley, et al., Molecular and Cellular Biology, 6:559-565, February 1986	
	BE	Habeeb, A.F.S.A., Analytical Biochemistry, 56:60-65, 1973	
 	BF	Hann et al., J. Chem. Soc. Perkin Trans., 1, 307-314, 1982	
 _	BG	Holladay et al. Tetrahedron Letters, 24(41):4401-4404, 1983	
	ВН	Houghten et al. Cell, Vol. 93, pp. 165-176, April 17, 1998	L
\vdash	BI	Houghten et al., Vaccines 86, Cold Spring Harbor Laboratory, pp. 21-25, 1986	
	BJ	Hruby et al., Life Sciences, 31:189-199, 1982	
lacksquare	вк	Hudson et al. Int. J. Protein Res., 14:177-185, 1979	L
$oxed{oxed}$	BL	Huse, et al., Science, 246:1275-1281, December 1989	
	ВМ	Jennings-White et al., Tetrahedron Letters, 23(25):2533-2534, 1982	
	BN	Kamber et al., Helvetica Chimica Acta, 63(Fasc. 4):899-915, 1980	
	во	Kobayashi et al., J. Exp. Med., Vol. 191, No. 2, 275-285	
	BP	Köhler et al., Nature, 256:495-497, 1975	
	BQ	Kong et al., Immunology and Cell Biology, 77:188-193, January 1999	
	BR	Kong et al., Nature, 397:315-323, 1999	
	BS	Kornak et al., Cell, 104:205-215, 2001	
	BT	Kozbor et al., Immunology Today, 4(3):72-79, 1983	
	BU	Lacey et al., Amer. J. of Pathology, 157(2):435-448, 2000	
	BV	Li Y.P. et al., Nature Genetics, 23:447-451, 1999	
	BW	Li J. et al., PNAS, 97(4):1566-1571, 2000	
	BX	Livingstone, David M., Methods in Enzymology, Affinity Techniques, 723-731, 1974	
	BY	Logan et al., Proc. Natl. Acad. Sci. USA, 81:3655-3659, June 1984	
	BZ	Mackett et al., Proc. Natl. Acad. Sci. USA 79:7415-7519, December 1982	
	CA	Mackett et al., Journal of Virology, 49(3):857-864, March 1984	
(CB	McOsker et al., J. Bone & Mineral Research, Twelfth Annual Meeting of the American Societ for Bone	
\vdash	 	and Mineral Research, 5(Supp 2):S105, No. 128, Abstract, Aug. 28-31, 1990	<u> </u>
├ ──	CC	Moore et al., Techniques in Protein Chemistry VII, Marsak (ed.) 81-91, 1996	
 	CE	Morley, J.S., Trends Pharm. Sci., 463-468, December 1980	
├─┼	CF	Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855, November 1984 Mortensen et al., J. Clinical Endrocrinology and Metabolism, 83(2):396-402, 1998	
┝╼╂╸	CG	Nakagawa, N., et al., "RANK is the essential signaling receptor for osteoclast differentiation	
	1	factor in osteoclastogensis" Database Chemical Abstracts on STN, No. 130:166173, Abstract,	İ
<u></u>		Biochem. Biophys. Res. Commun., 1998, 253(2), 395-400	
	СН	Neuberger et al., Nature, 312:604-608, December 1984	
	CI	Nicholson et al., J. Clinical Investigation, 78:355-360, August 1986	
	CJ	Panicali et al., Proc. Natl. Acad. Sci. USA, 79:4927-4931, August 1982	
┝┰╂╌	CK	Peppel et al., J. Exp. Med., 174:1483-1489, December 1991	
$\vdash \mathcal{W}$	CL	Ponder et al., J. Mol. Biol., 193:775-791, 1987	
1 1 VAT	CM	Scimeca, J.C., Bone, 26(3):207-213, 2000	
<u>/Lyy/</u>	TOIA	Shalhoub, V. et al., British J. of Haematology, 111:501-512, 2000	

Examiner	/Leonard Williams/ (08/28/2007)	Date
Signature	/Leonard Williams/ (08/28/2007)	Considered
Olgitatoro		Considered

PTC/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it forthers a waited CAUM control of the control

Su	bstitute for form 1449/PT	0		Complete If Known		
				Application Number	Not Yet Assigned	
	NFORMATIC	ON DIS	CLOSURE	Filing Date	Concurrently Herewith	
8	STATEMENT	BY AF	PPLICANT	First Named Inventor	Mark I. Greene	
ļ				Art Unit	1653	
	(use as many	sheels as ne	cessary)	Examiner Name	A. Mohamed	
Sheet	3	of	3	Attorney Docket Number	4040/1K201US2	

/LW	// co	Shalhoub et al., J. Cellular Biochem., 72(2):251-261,1999	_
	CP	Sietsema et al., Drugs Exptl. Clin. Res., XV(9):389-396, 1989	1
	CQ	Simonet et al., Cell, 89(2):309-319, 1997	
	CR	Singer et al., J. Clinical Endocrinology and Metabolism, 83(6):1906-1910, 1998	1
	CS	Siris et al., J. Bone and Mineral Research, 13(6):1032-1038, 1998	
	CT	Smith et al., Journal of Virology, 46:584-593, May 1983	
	CU	Spatola, A. F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, 7:267-357, 1983	T
	CV	Spatola et al., Life Sciences, 38:1243-1249, 1986	
\Box	cw	Suda et al., Endocrine Reviews 20(3):345-357, June 1999	
	CX	Suda et al., Novartis Found Symp, 232: 235, 2001 (Abstract)	
	CY	Takamatsu et al., EMBRO Journal, 6(2):307-311, 1987	
	CZ	Takasaki et al., Nature Biotechnology, 15:1266-1270, 1997	
igspace	DA	Takeda et al., Nature 314:452-454, 1985	
\sqcup	DB	Tam et al., Synthesis, 955-957, December 1979	1
	DC	Van Beek E., J. Bone and Mineral Research, 11(10):1492-1497, 1996	
	DD_	Weitzmann et al., J. of Bone and Mineral Research, 16(2):328-337, 2001	T
	DE	Williams et al., Immunology, 84:433-439, 1995	1
ш	DF	Wong et al. Journal of Leukocyte Biology, 65:715-724, June 1999	T
	DG	Yamaguchi et al., J. of Biological Chemistry, 273(9):5177-5123, Feb. 28, 1998	
	∠ DH	Yasuda et al. Proc. Natl. Acad. Sci. USA., Vol. 95 pp. 3597-3602, March 1998	1
$\perp \mathbf{Y}$	DI	Zhang et al., Nature Biotechnology, 14:472-475, April 1996	
L/LV	V/ DJ	Zhang et al., Nature Biotechnology, 15:150-154, 1997	1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner I	" 114/00 (00 (00 (00 00)	Date
0	Leonard Williams/ (08/28/2007)	1000
Signature	reconard williams (00/20/2007)	Considered

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.